ABCR  Vol.2 No.3 , July 2013
The Association between Sentinel Lymph Node Metastasis and Ki-67 Labeling Index
ABSTRACT

Background: The purpose of this study was to elucidate the association between sentinel lymph node (SLN) metastasis and Ki67 labeling index and to elucidate whether Ki-67 was useful or not for prediction of SLN metastasis in breast cancer. Methods: We identified 343 invasive breast cancer patients with sentinel lymph node biopsy (SLNB) from 2003 to 2012. The association between SLN status and clinicopathological features, molecular subtypes and Ki-67 labeling index were evaluated. Results: SLN metastasis was detected in 79 patients (23.0%). SLN metastasis was significantly associated with clinical T-stage (p = 0.0003), lymphovascular involvement (LVI) (p < 0.0001). Ki-67 labeling index of primary tumor was significantly lower in SLN positive patients (p = 0.0331), and Ki-67 cut-off point of 7.5% was useful for dividing SLN positive from negative (p = 0.0197). Conclusion: Low value of Ki-67 labeling index, in addition to progression of clinical T-stage and presence of LVI, is significantly associated with SLN metastasis, and it seems to be useful to consider Ki-67 labeling index for SLN metastasis prediction.


Cite this paper
Koyama, Y. , Ichikawa, H. , Sakata, J. , Sakata, E. , Tatsuda, K. , Hasegawa, M. , Toshikawa, C. , Manba, N. , Ikarashi, M. and Wakai, T. (2013) The Association between Sentinel Lymph Node Metastasis and Ki-67 Labeling Index. Advances in Breast Cancer Research, 2, 60-65. doi: 10.4236/abcr.2013.23011.
References
[1]   P. P. Rosen, S. Groshen, D. W. Kinne and L. Norton, “Factors Influencing Prognosis in Node-Negative Breast Carcinoma: Analysis of 767 T1N0M0/T2N0M0 Patients with Long-Term Follow Up,” Journal of Clinical Oncology, Vol. 11, No. 11, 1993, pp. 2090-2100.

[2]   “Consensus Statement Treatment of Early-Stage Breast Cancer. National Institutes of Health Consensus Development Panel,” Journal of the National Cancer Institute Monographs, No. 11, 1992, pp. 1-5.

[3]   J. H. Lee, S. H. Kim, Y. J. Suh, B. Y. Shim and H. K. Kim, “Predictors of Axillary Lymph Node Metastasis (ALNM) in a Korean Population with T1-2 Breast Carcinoma: Triple Negative Breast Cancer Has a High Incidence of ALNM Irrespective of the Tumor Size,” Breast Cancer Research and Treatment, Vol. 42, No. 1, 2010, pp. 30-36. doi:10.4143/crt.2010.42.1.30

[4]   G. Cserni, S. Bianchi, V. Vezzosi, R. Arisio, R. Bori, J. L. Peterse, A. Sapino, M. Drijkoningen, J. Kulka, V. Eusebi, M. P. Foschini, J. P. Bellocq, C. Marin, S. Thorstenson, I. Amendoeira, A. Reiner-Concin and T. Decker, “Sentinellymph Node Biopsy and Non-Sentinelnode Involvement in Special Type Breast Carcinomas with a Good Prognosis,” European Journal of Cancer, Vol. 43, No. 9, 2007, pp. 1407-1414. doi:10.1016/j.ejca.2007.04.004

[5]   G. Canavese, M. Gipponi, A. Catturich, C. Vecchio, D. Tomei, G. Nicoló, F. Carli, B. Spina, L. Bonelli, G. Villa, F. Buffoni, P. Bianchi, A. Agnese and G. Mariani, “Technical Issues and Pathologic Implications of Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Patients,” Journal of Surgical Oncology, Vol. 77, No. 2, 2001, pp. 81-87. doi:10.1002/jso.1074

[6]   S. J. Crabb, M. C. Cheang, S. Leung, T. Immonen, T. O. Nielsen, D. D. Huntsman, C. D. Bajdik and S. K. Chia, “Basalbreast Cancermolecularsubtype Predicts for Lower Incidence of Axillary Lymph Node Metastases in Primary Breast Cancer,” Clinical Breast Cancer, Vol. 8, No. 3, 2008, pp. 249-256. doi:10.3816/CBC.2008.n.028

[7]   A. Barth, P. H. Craig and M. J. Silverstein, “Predictors of Axillary Lymph Node Metastases in Patients with T1 Breast Carcinoma,” Cancer, Vol. 79, No. 10, 1997, pp. 1918-1922. doi:10.1002/(SICI)1097-0142(19970515)79:10<1918::AID-CNCR12>3.0.CO;2-Y

[8]   I. A. Olivotto, J. S. Jackson, D. Mates, S. Andersen, W. Davidson, C. J. Bryce and J. Ragaz, “Prediction of Axillary Lymph Node Involvement of Women with Invasive Breast Carcinoma: A Multivariate Analysis,” Cancer, Vol. 83, No. 5, 1998, pp. 948-955. doi:10.1002/(SICI)1097-0142(19980901)83:5<948::AID-CNCR21>3.0.CO;2-U

[9]   M. J. Silverstein, E. D. Gierson, J. R. Waisman, W. J. Colburn and P. Gamagami, “Predictingaxillary Node Positivity in Patients with Invasive Carcinoma of the Breast by Using a Combination of T Category and Palpability,” The Journal of the American College of Surgeons, Vol. 180, No. 6, 1995, pp. 700-704.

[10]   M. J. Silverstein, K. A. Skinner and T. J. Lomis, “Predicting Axillary Nodal Positivity in 2282 Patients with Breast Carcinoma,” World Journal of Surgery, Vol. 25, No. 6, 2001, pp. 767-772. doi:10.1007/s00268-001-0003-x

[11]   C. Gajdos, P. I. Tartter and I. J. Bleiweiss, “Lymphatic Invasion, Tumor Size, and Age Are Independent Predictors of Axillary Lymph Node Metastases in Women with T1 Breast Cancers,” Annals of Surgery, Vol. 230, No. 5, 1999, pp. 692-696. doi:10.1097/00000658-199911000-00012

[12]   P. H. Gann, S. A. Colilla, S. M. Gapstur, D. J. Winchester and D. P. Winchester, “Factors Associated with Axillary Lymph Node Metastasis from Breast Carcinoma: Descriptive and Predictive Analyses,” Cancer, Vol. 86, No. 8, 1999, pp. 1511-1519. doi:10.1002/(SICI)1097-0142(19991015)86:8<1511::AID-CNCR18>3.0.CO;2-D

[13]   G. Viale, S. Zurrida, E. Maiorano, G. Mazzarol, G. Pruneri, G. Paganelli, P. Maisonneuve and U. Veronesi, “Predicting the Status of Axillary Sentinel Lymph Nodes in 4351 Patients with Invasive Breast Carcinoma Treated in a Single Institution,” Cancer, Vol. 103, No. 30, 2005, pp. 492-500. doi:10.1002/cncr.20809

[14]   X. Lu, X. Lu, Z. C. Wang, J. D. Iglehart, X. Zhang and A. L. Richardson, “Predicting Features of Breast Cancer with Gene Expression Patterns,” Breast Cancer Research and Treatment, Vol. 108, No. 2, 2008, pp. 191-201. doi:10.1007/s10549-007-9596-6

[15]   H. Liu, Q. Fan, Z. Zhang, X. Li, H. Yu and F. Meng, “Basal-HER2 Phenotype Shows Poorer Survival than BasalLike Phenotype in Hormone Receptor-Negative Invasive Breast Cancers,” Human Pathology, Vol. 39, No. 2, 2008, pp. 167-174. doi:10.1016/j.humpath.2007.06.012

[16]   B. Van Calster, I. VandenBempt, M. Drijkoningen, N. Pochet, J. Cheng, S. Van Huffel, W. Hendrickx, J. Decock, H. J. Huang, K. Leunen, F. Amant, P. Berteloot, R. Paridaens, H. Wildiers, E. Van Limbergen, C. Weltens, D. Timmerman, T. Van Gorp, A. Smeets, W. Van den Bogaert, I. Vergote, M. R. Christiaens and P. Neven, “Axillary Lymph Node Status of Operable Breast Cancers by Combined Steroid Receptor and HER-2 Status: Triple Positive Tumours Are More Likely Lymph Node Positive,” Breast Cancer Research and Treatment, Vol. 113, No. 1, 2009, pp. 181-187. doi:10.1007/s10549-008-9914-7

[17]   M. J. Kim, J. Y. Ro, S. H. Ahn, H. H. Kim, S. B. Kim and G. Gong, “Clinicopathologic Significance of the BasalLike Subtype of Breast Cancer: A Comparison with Hormone Receptor and Her2/Neu-Overexpressing Phenotypes,” Human Pathology, Vol. 37, No. 9, 2006, pp. 1217-1226. doi:10.1016/j.humpath.2006.04.015

[18]   P. L. Nguyen, A. G. Taghian, M. S. Katz, A. Niemierko, R. F. AbiRaad, W. L. Boon, J. R. Bellon, J. S. Wong, B. L. Smith and J. R. Harris, “Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated with Local and Distant Recurrence after Breast-Conserving Therapy,” Journal of Clinical Oncology, Vol. 26, No. 14, 2008, pp. 2373-2378. doi:10.1200/JCO.2007.14.4287

[19]   K. D. Voduc, M. C. Cheang, S. Tyldesley, K. Gelmon, T. O. Nielsen and H. Kennecke, “Breast Cancer Subtypes and the Risk of Local and Regional Relapse,” Journal of Clinical Oncology, Vol. 28, No. 10, 2010, pp.1684-1691. doi:10.1200/JCO.2009.24.9284

[20]   F. Reyal, R. Rouzier, B. Depont-Hazelzet, M. A. Bollet, J. Y. Pierga, S. Alran, R. J. Salmon, V. Fourchotte, A. Vincent-Salomon, X. Sastre-Garau, M. Antoine, S. Uzan, B. Sigal-Zafrani and Y. De Rycke, “The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma,” PLoS One, Vol. 6, No. 5, 2011, Article ID: e20297. doi:10.1371/journal.pone.0020297

[21]   S. Buglioni, F. Di Filippo, I. Terrenato, B. Casini, E. Gallo, F. Marandino, C. L. Maini, R. Pasqualoni, C. Botti, S. Di Filippo, E. Pescarmona and M. Mottolese, “Quantitative Molecular Analysis of Sentinel Lymph Node May Be Predictive of Axillary Node Status in Breast Cancer Classified by Molecular Subtypes,” PLoS One, Vol. 8, No. 3, 2013, Article ID: e58823. doi:10.1371/journal.pone.0058823

[22]   C. Mazouni, F. Rimareix, M. C. Mathieu, C. Uzan, C. Bourgier, F. André, S. Delaloge and J. R. Garbay, “Outcome in Breast Molecular Subtypes According to Nodalstatus and Surgical Procedures,” American Journal of Surgery, Vol. 205, No. 6, 2013, pp. 662-667. doi:10.1016/j.amjsurg.2012.06.006

[23]   A. E. Giuliano, K. K. Hunt, K. V. Ballman, P. D. Beitsch, P. W. Whitworth, P. W. Blumencranz, A. M. Leitch, S. Saha, L. M. McCall and M. Morrow, “Axillary Dissection vs No Axillary Dissection in Women with Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial,” JAMA, Vol. 305, No. 6, 2011, pp. 569-575. doi:10.1001/jama.2011.90

[24]   V. Galimberti, B. F. Cole, S. Zurrida, G. Viale, A. Luini, P. Veronesi, P. Baratella, C. Chifu, M. Sargenti, M. Intra, O. Gentilini, M. G. Mastropasqua, G. Mazzarol, S. Massarut, J. R. Garbay, J. Zgajnar, H. Galatius, A. Recalcati, D. Littlejohn, M. Bamert, M. Colleoni, K. N. Price, M. M. Regan, A. Goldhirsch, A. S. Coates, R. D. Gelber and U. Veronesi, “International Breast Cancer Study Group Trial 23-01 Investigators, “Axillary Dissection versus No Axillary Dissection in Patients with Sentinel-Node Micrometastases (IBCSG 23-01): A Phase 3 Randomised Controlled Trial,” Lancet Oncology, Vol. 14, No. 4, 2013, pp. 297-305. doi:10.1016/S1470-2045(13)70035-4

[25]   O. Gentilini and U. Veronesi, “Abandoning Sentinel Lymph Node Biopsy in Early Breast Cancer? A New Trial in Progress at the European Institute of Oncology of Milan (SOUND: Sentinel Node vs Observation after Axillary UltraSouND),” Breast, Vol. 21, No. 5, 2012, pp. 678-681. doi:10.1016/j.breast.2012.06.013

[26]   B. Bonanni, M. Puntoni, M. Cazzaniga, G. Pruneri, D. Serrano, A. Guerrieri-Gonzaga, Gennari A, M. S. Trabacca, V. Galimberti, P. Veronesi, H. Johansson, V. Aristarco, F. Bassi, A. Luini, M. Lazzeroni, C. Varricchio, G. Viale, P. Bruzzi, and A. Decensi, “Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial,” Journal of Clinical Oncology, Vol. 30, No. 21, 2012, pp. 2593-2600. doi:10.1200/JCO.2011.39.3769

[27]   R. Yerushalmi, R. Woods, P. M. Ravdin, M. M. Hayes and K. A. Gelmon, “Ki67 in Breast Cancer: Prognostic and Predictive Potential,” Lancet Oncology, Vol. 11, No. 2, 2010, pp. 174-183. doi:10.1016/S1470-2045(09)70262-1

[28]   C. Strand, M. Bak, S. Borgquist, G. Chebil, A. K. Falck, M. L. Fjallskog, D. Grabau, I. Hedenfalk, K. Jirstrom, M. Klintman, P. Malmstrom, H. Olsson, L. Rydén, O. Stal, P. O. Bendahl and M. Ferno, “The Combination of Ki67, Histological Grade and Estrogen Receptor Status Identifies a Low-Risk Group among 1854 Chemo-Naive Women with N0/N1 Primary Breast Cancer,” Springerplus, Vol. 2. No. 1, 2013, p. 111. doi:10.1186/2193-1801-2-111

[29]   A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thürlimann and H. J. Senn and Panel Members, “Strategies for Subtypes—Dealing with the Diversity of Breast Cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011,” Annals of Oncology, Vol. 22, No. 8, 2011, pp. 1736-1747. doi:10.1093/annonc/mdr304

[30]   R. L. Jones, J. Salter, R. A’Hern, A. Nerurkar, M. Parton, J. S. Reis-Filho, I. E. Smith and M. Dowsett, “Relationship between Oestrogen Receptor Status and Proliferation in Predicting Response and Long-Term Outcome to Neoadjuvant Chemotherapy for Breast Cancer,” Breast Cancer Research and Treatment, Vol. 119, No. 2, 2010, pp. 315-323. doi:10.1007/s10549-009-0329-x

[31]   G. Contesso, H. Mouriesse, S. Friedman, J. Genin, D. Sarrazin and J. Rouesse, “The Importance of Histologicgrade in Long-Term Prognosis of Breast Cancer: A Study of 1010 Patients, Uniformly Treated at the Institut GustaveRoussy,” Journal of Clinical Oncology, Vol. 5, No. 9, 1987, pp. 1378-1386.

 
 
Top